Mom Launches New Biotech After Saving Daughter With Custom Drug

A mother who helped create a one-of-a-kind medicine for her dying daughter is turning that miracle into hope for other families facing rare diseases.

Julia Vitarello's daughter Mila received a custom-designed drug eight years ago, tailored specifically to her unique genetic mutation. That bespoke treatment gave Mila precious extra years of life when nothing else could help.

Now Vitarello is starting a new biotech company to scale up this personalized approach. Her goal is to make these individualized therapies accessible to more patients who need them, not just one child at a time.

This isn't Vitarello's first attempt at turning Mila's story into broader impact. Her previous company, EveryONE Medicines, recently closed after FDA guidance on customized therapies fell short of what investors needed to move forward.

But Vitarello isn't giving up. She's actively seeking new funding partners who share her vision of making personalized medicine a reality for families desperate for options.

Why This Inspires

What makes this story powerful is a mother's refusal to let one success story remain just one story. Vitarello could have stopped after saving her own daughter, but instead she's dedicating herself to helping other families facing impossible diagnoses.

The science of personalized medicine has proven it can work. Mila's treatment showed that drugs designed for a single patient's specific genetic mutation can be effective. The challenge now is economics and regulation, not biology.

Vitarello's persistence through setbacks shows the determination driving rare disease advocacy. When EveryONE Medicines folded, she didn't walk away. She's regrouping, learning from what didn't work, and building something new.

Her efforts come at a promising time. The FDA has shown interest in creating pathways for customized therapies, even if current guidance hasn't gone far enough yet. Every company working in this space helps push regulators and the industry toward solutions.

For families watching their children suffer from ultra-rare genetic diseases, Vitarello represents more than business innovation. She represents the possibility that the next breakthrough treatment could be designed just for them.

The path forward won't be easy, but Vitarello has already done the impossible once.